7results about How to "Activate immune response" patented technology

The application discloses a CD40L-IL-2 fusion protein and a preparation method and application thereof in preparing a tumor treatment drug. The fusion protein comprises a CD40L trimer or a variant thereof and a cytokine IL-2 or a variant thereof; the CD40L trimer comprises three CD40L monomers connected. The fusion protein provided by the application can synergistically activate APC-dependent antigen presentation and T cell-mediated immune killing, forms a closed-loop anti-tumor immune response of 'antigen presentation-immune initiation-effect amplification', and provides an effective strategy for treating tumors.

The application discloses application of an immune elicitor protein FvXynC and a protein combination in plant disease resistance, and belongs to the technical field of plant immune elicitors. A new immune elicitor protein FvXynC is found from F. pseudograminearum, and the immune elicitor protein has the core functions of activating plant immune response and improving plant resistance to F. pseudograminearum, can be used as an efficient plant immune inducer, provides a new technical path for plant disease resistance improvement and green plant disease control, and has important agricultural application value. The FvXynC and the immune elicitor protein FvGH43A are compounded, so that the resistance level of corn to F. pseudograminearum can be synergistically improved, and the problem that the plant disease control effect of a single immune elicitor protein is limited is solved.

This invention discloses a type B influenza virus T4 peptide that can induce cellular immune responses and its applications, belonging to the fields of immunotherapy and immunoassay technology. The immunogenicity of this long peptide (SEQ ID NO.1, named T4) was verified in 21 volunteers using ELISpot assay. Results showed that T4 was positive in 5 individuals, with a positive rate of 23.81%. ELISpot assay of human PBMCs (IFN-γ secretory cells) showed that T4 induced an immune response of up to 3060 SFCs / 10 in the population. 6 PBMC. Therefore, this peptide has good immunogenicity and universality in the population, and can be used as a specific detection peptide for monitoring cellular immune levels. At the same time, this peptide can effectively activate the T cell immune response in the population, and has the potential to be used as a candidate vaccine epitope peptide for the design of novel vaccines.

This invention discloses the preparation and application of radiofrequency thermoresponsive platinum ion crosslinked black phosphorus nanogel. The nanogel has a core-shell structure, comprising a core composed of a radiofrequency thermosensitive agent and chemotherapeutic drugs, and a shell constructed from a thermosensitive nanopolymer. The thermosensitive nanogel BP-Pt@PNA prepared using the above components exhibits radiofrequency thermosensitive properties. Simultaneously, the introduction of the thermosensitive nanopolymer improves the stability of the radiofrequency thermosensitive agent and chemotherapeutic drugs, enabling long-term drug retention and fully leveraging the synergistic effect of non-invasive radiofrequency thermotherapy and chemotherapy. This drug-loaded nanogel can achieve multimodal treatment applications, including non-invasive radiofrequency thermotherapy-chemotherapy synergistic antitumor therapy and invasive radiofrequency ablation-chemotherapy-vascular embolization synergistic antitumor therapy, demonstrating significant clinical translational potential.

The application discloses a postoperative auxiliary comprehensive treatment system with spatiotemporal response and a preparation method and application thereof, and relates to the fields of biology and medicine and the technical field of pharmaceutical preparations. The system comprises a temperature-sensitive hydrogel matrix, an anti-inflammatory drug dispersed in the hydrogel matrix, and nanoparticles loaded with an immunomodulator and dispersed in the hydrogel matrix. In an embodiment of the application, a postoperative auxiliary treatment comprehensive system is successfully constructed, and curcumin and MPDA encapsulating R848 are simultaneously loaded in the gel support. The small molecule curcumin is preferentially released from the gel to play an anti-inflammatory role, and R848 needs to be gradually released from the mesopore of the MPDA and the gel, so that the immune microenvironment can be improved after the anti-inflammatory curcumin promotes wound healing.

This invention relates to the field of traditional Chinese medicine cultivation technology, specifically the application of D6-abelacterol, and particularly its application in promoting the growth of Panax notoginseng, inducing resistance, and improving its quality. Experiments have shown that D6-abelacterol significantly enhances the resistance of Panax notoginseng to pathogens such as black spot disease, improving its disease resistance; simultaneously, it promotes plant growth, significantly increasing the yield and quality of Panax notoginseng, exhibiting a significant growth-promoting effect. The D6-abelacterol provided by this invention is a natural product, possessing environmentally friendly, low-toxicity, and green properties, laying the foundation for the development of the Panax notoginseng industry.

This invention discloses the application of PACAP peptides as plant immunomodulators, belonging to the field of plant immunology technology. This invention is the first to apply PACAP to a plant system, discovering that it can act as a novel plant immunomodulator to regulate plant immune responses, thereby enhancing plant resistance to pathogenic microorganisms. Experimental results show that PACAP can rapidly induce intracellular calcium ion influx in Arabidopsis thaliana cells, activate the MAPK signaling pathway, and upregulate the expression of early immune marker genes such as FRK1. Furthermore, PACAP treatment significantly improves plant resistance to pathogens such as *Pseudomonas syringae* and *Ralstonia solanacearum*. This invention also confirms that not only does the full-length PACAP (1-38) possess plant immune-promoting activity, but its N-terminal truncated peptide (1-27) and receptor antagonist fragment (6-38) also have plant immune-inducing functions. This invention provides a new technical solution for the development of plant immune inducers.